Last checked at 7 Jul 2011 07:20
BEXIMCO PHARMACEUTICALS LTD.
7 July 2011
Stock Dividend Issued
Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) announces that the stock dividend proposed on 28 April 2011 and passed by shareholders at the Annual General Meeting on 2 July 2011 has today been credited to shareholder accounts.
The Company has applied for admission of 9,409,573 new GDRs issued in respect of the stock dividend to be admitted to trading on the London Stock Exchange's AIM market and admission is expected to occur on or around 12 July 2011.
Following admission, the total issued share capital of the Company will be 251,767,810 ordinary shares of Taka 10 ("Ordinary Shares"), of which 56,457,439 will be represented by GDRs, each representing one Ordinary Share of Taka 10. The new Ordinary Shares will rank pari passu in all respects with the existing issued Ordinary Shares, all having voting rights.
For further enquiries please visit www.beximco-pharma.com or contact:
Beximco Pharma
Nazmul Hassan, MP
Managing Director & CEO
Tel: +880 2 8619151, Ext. 2080
Md. Asad Ullah, FCS, Executive Director & Company Secretary
Tel: +880 2 8618220, Ext.1140
Libertas Capital
Jakob Kinde / Thilo Hoffmann
Tel: +44 (0)20 7569 9650
Financial Dynamics
Jonathan Birt / Susan Quigley
Tel: +44 (0)20 7269 7169
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.
The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.